A double-blind, placebo-controlled, randomized withdrawal study of canakinumab in pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517155-13-00

Acronym

PAPA-Can

Enrollment

Registered

2024-11-19

Start date

2024-02-02

Completion date

Unknown

Last updated

2024-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PAPA syndrome

Brief summary

To determine whether canakinumab administered every 4 weeks is able to prevent disease flares when compared to placebo in canakinumab-responder patients.

Interventions

DRUGPlacebo is solution for injection (150 mg/ml) contained in vials equal to those of Canakinumab and appears identical to the Test product. Placebo is provided by Novartis pharma.

DRUGIlaris 150 mg/ml solution for injection

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To determine whether canakinumab administered every 4 weeks is able to prevent disease flares when compared to placebo in canakinumab-responder patients.	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026